EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access · CC BY 4.0

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection

Sunwen Chou, Drew J Winston, Robin K Avery iD, Catherine Cordonnier, Rafael F Duarte, Shariq Haider, Johan Maertens, Karl S Peggs, Carlos Solano, Jo-Anne H Young iD, Joan Gu, Ginger Pocock und 1 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae469 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Sunwen Chou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Drug Resistance, Viral, Antiviral Agents, Cytomegalovirus Infections, Ribonucleosides. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc, VA, US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Among 547 patients receiving maribavir or valganciclovir for first-episode cytomegalovirus infection after hematopoietic cell transplant, the treatment response rate was 69.6% and 77.4% respectively. Development of maribavir and ganciclovir resistance was compared after receiving either drug.

Methods

Viral mutations conferring drug resistance were analyzed in plasma DNA extracts at baseline and posttreatment.

Results

Prior antiviral drug exposure was limited, with only 2 instances of baseline drug resistance detected. An equal number (n = 241) received valganciclovir or maribavir for at least 21 days (median, 55–56 days). Among them, drug resistance mutations were detected in 24 (10%) maribavir recipients at 35–125 days (median, 56 days) after starting therapy, including in 12 of 14 who experienced a viral load rebound while on therapy. Ganciclovir resistance mutations developed in 6 (2.5%) valganciclovir recipients at 66–110 days (median, 90 days). One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir resistance in vitro. Viral clearance was confirmed in 17 (74%) of 23 patients with emergent maribavir resistance after retreatment with an alternative CMV antiviral drug.

Conclusions

After 3–8 weeks of therapy, maribavir resistance emerged earlier and more frequently than ganciclovir resistance but was usually treatable using alternative therapy. Clinical Trials Registration. NCT02927067 (AURORA).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, ViralAntiviral AgentsCytomegalovirus InfectionsRibonucleosidesGanciclovirBenzimidazolesCytomegalovirusHumansFemaleMaleMiddle AgedAdultValganciclovirViral LoadMutationHematopoietic Stem Cell TransplantationAgedTreatment OutcomeYoung AdultDNA, ViralDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

antiviral drug resistanceantiviral therapycytomegalovirusmaribavirvalganciclovir

Substanzen

maribavirAntiviral AgentsRibonucleosidesGanciclovirBenzimidazolesValganciclovirDNA, ViralDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
  • Research and Development Service, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
  • Los Angeles Medical Center, University of California, Los Angeles, California, USA.
  • Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
  • Haematology Department, Henri Mondor Hôpital, Assistance Publique-Hopitaux de Paris, and Université Paris-Est-Créteil, Créteil, France.
  • Department of Haematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

ORCID-Profile: Robin K Avery, Jo-Anne H Young

Förderung

  • Takeda Development Center Americas, Inc
  • VA
  • US
  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Department of Veterans Affairs

Zitieren

APA

Chou, S., Winston, D. J., Avery, R. K., Cordonnier, C., Duarte, R. F., Haider, S., Maertens, J., Peggs, K. S., Solano, C., Young, J. H., Gu, J., Pocock, G., & Papanicolaou, G. A. (2025). Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae469

Vancouver

Chou S, Winston DJ, Avery RK, Cordonnier C, Duarte RF, Haider S, et al. Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae469

BibTeX
@article{Chou2025,
  author = {Chou, Sunwen and Winston, Drew J and Avery, Robin K and Cordonnier, Catherine and Duarte, Rafael F and Haider, Shariq and Maertens, Johan and Peggs, Karl S and Solano, Carlos and Young, Jo-Anne H and Gu, Joan and Pocock, Ginger and Papanicolaou, Genovefa A},
  title = {Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae469}
}
Kostenlos starten →